Oric Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

ORIC Pharmaceuticals

09/08/2024 16:49

* Oric Pharmaceuticals Inc  ORIC.OQ   ORIC.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 12 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Oric Pharmaceuticals Inc
is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $18.00​, above​ its last closing price
of $8.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.45       -0.44      -0.37     Beat    15.2
 Dec. 31 2024  -0.49       -0.49      -0.49     Met     -0.7
 Sep. 30 2023  -0.46       -0.46      -0.44     Beat    4.7​
 Jun. 30 2023  -0.57       -0.57      -0.50     Beat    12.1
 ​​Mar.        -0.54       -0.54      -0.53     Beat    1.9
 31 2023                                                
 Jan. 1 0001   -0.51       -0.54      -0.52     Beat    3​
 Sep. 30 2022  -0.55       -0.55      -0.63     Missed  -13.8
 Jun. 30 2022  -0.61       -0.60      -0.51     Beat    15
 This summary was machine generated August 9 at 15:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)